[en] Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by focal inflammatory lesions and prominent demyelination. Even though the currently available therapies are effective in treating the initial stages of disease, they are unable to halt or reverse disease progression into the chronic progressive stage. Thus far, no repair-inducing treatments are available for progressive MS patients. Hence, there is an urgent need for the development of new therapeutic strategies either targeting the destructive immunological demyelination or boosting endogenous repair mechanisms. Using in vitro, ex vivo, and in vivo models, we demonstrate that selective inhibition of phosphodiesterase 4 (PDE4), a family of enzymes that hydrolyzes and inactivates cyclic adenosine monophosphate (cAMP), reduces inflammation and promotes myelin repair. More specifically, we segregated the myelination-promoting and anti-inflammatory effects into a PDE4D- and PDE4B-dependent process respectively. We show that inhibition of PDE4D boosts oligodendrocyte progenitor cells (OPC) differentiation and enhances (re)myelination of both murine OPCs and human iPSC-derived OPCs. In addition, PDE4D inhibition promotes in vivo remyelination in the cuprizone model, which is accompanied by improved spatial memory and reduced visual evoked potential latency times. We further identified that PDE4B-specific inhibition exerts anti-inflammatory effects since it lowers in vitro monocytic nitric oxide (NO) production and improves in vivo neurological scores during the early phase of experimental autoimmune encephalomyelitis (EAE). In contrast to the pan PDE4 inhibitor roflumilast, the therapeutic dose of both the PDE4B-specific inhibitor A33 and the PDE4D-specific inhibitor Gebr32a did not trigger emesis-like side effects in rodents. Finally, we report distinct PDE4D isoform expression patterns in human area postrema neurons and human oligodendroglia lineage cells. Using the CRISPR-Cas9 system, we confirmed that pde4d1/2 and pde4d6 are the key targets to induce OPC differentiation. Collectively, these data demonstrate that gene specific PDE4 inhibitors have potential as novel therapeutic agents for targeting the distinct disease processes of MS.
Disciplines :
Biochimie, biophysique & biologie moléculaire
Auteur, co-auteur :
Schepers, Melissa
Paes, Dean
Tiane, Assia
Rombaut, Ben
Piccart, Elisabeth
van Veggel, Lieve
Gervois, Pascal
Wolfs, Esther
Lambrichts, Ivo
Brullo, Chiara
Bruno, Olga
Fedele, Ernesto
Ricciarelli, Roberta
Ffrench-Constant, Charles
Bechler, Marie E.
van Schaik, Pauline
Baron, Wia
Lefevere, Evy
Wasner, Kobi
GRÜNEWALD, Anne ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Molecular and Functional Neurobiology
Ansi Chang, M.D., Tourtellotte, W.W., Rudick, R., Trapp, D., Bruce, Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 346 (2002), 165–173.
Ariga, M., Neitzert, B., Nakae, S., Mottin, G., Bertrand, C., Pruniaux, M.P., et al. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J. Immunol. 173:12 (2004), 7531–7538.
Avila, D.V., Myers, S.A., Zhang, J., Kharebava, G., McClain, C.J., Kim, H.Y., et al. Phosphodiesterase 4b expression plays a major role in alcohol-induced neuro-inflammation. Neuropharmacology 125 (2017), 376–385.
Bailey, C.H., Bartsch, D., Kandel, E.R., Toward a molecular definition of long-term memory storage. PNAS 93:24 (1996), 13445–13452.
Basole, C.P., Nguyen, R.K., Lamothe, K., Billis, P., Fujiwara, M., Vang, A.G., et al. Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8). Cells, 11(4), 2022.
Batten, M., Li, J., Yi, S., Kljavin, N.M., Danilenko, D.M., Lucas, S., et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 7:9 (2006), 929–936.
M. Bear BC, M. Paradiso. Neuroscience: exploring the brain. Wilkins CLW, editor2007.
Bechler, M.E., A neuron-free microfiber assay to assess myelin sheath formation. Methods Mol. Biol. 1936 (2019), 97–110.
Bielekova, B., Lincoln, A., McFarland, H., Martin, R., Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J. Immunol. 164:2 (2000), 1117–1124.
Bielekova, B., Richert, N., Howard, T., Packer, A.N., Blevins, G., Ohayon, J., et al. Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood–brain barrier disruption in multiple sclerosis. Mult. Scler. 15:10 (2009), 1206–1214.
Blokland, A., Heckman, P., Vanmierlo, T., Schreiber, R., Paes, D., Prickaerts, J., Phosphodiesterase type 4 inhibition in CNS diseases. Trends Pharmacol. Sci. 40:12 (2019), 971–985.
Bolger, G.B., Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell. Signal. 6:8 (1994), 851–859.
Branch, S.Y., Beckstead, M.J., Methamphetamine produces bidirectional, concentration-dependent effects on dopamine neuron excitability and dopamine-mediated synaptic currents. J. Neurophysiol. 108:3 (2012), 802–809.
Braun, N.N., Reutiman, T.J., Lee, S., Folsom, T.D., Fatemi, S.H., Expression of phosphodiesterase 4 is altered in the brains of subjects with autism. Neuroreport 18:17 (2007), 1841–1844.
Bruno, O., Fedele, E., Prickaerts, J., Parker, L.A., Canepa, E., Brullo, C., et al. GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. Br. J. Pharmacol. 164:8 (2011), 2054–2063.
Cavalloro, V., Russo, K., Vasile, F., Pignataro, L., Torretta, A., Donini, S., et al. Insight into GEBR-32a: chiral resolution, absolute configuration and enantiopreference in PDE4D inhibition. Molecules, 25(4), 2020.
Charles FRJMF-C. Remyelination in the CNS: from biology to therapy. Nature Reviews Neuroscience. 2008;9:839-55.
Compston, A., Coles, A., Multiple sclerosis. Lancet 372:9648 (2008), 1502–1517.
Cui, S.Y., Yang, M.X., Zhang, Y.H., Zheng, V., Zhang, H.T., Gurney, M.E., et al. Protection from amyloid beta peptide-induced memory, biochemical, and morphological deficits by a phosphodiesterase-4d allosteric inhibitor. J. Pharmacol. Exp. Ther. 371:2 (2019), 250–259.
Ding, Z.B., Han, Q.X., Wang, Q., Song, L.J., Chu, G.G., Guo, M.F., et al. Fasudil enhances the phagocytosis of myelin debris and the expression of neurotrophic factors in cuprizone-induced demyelinating mice. Neurosci. Lett., 753, 2021, 135880.
Dos Santos, N., Novaes, L.S., Dragunas, G., Rodrigues, J.R., Brandao, W., Camarini, R., et al. High dose of dexamethasone protects against EAE-induced motor deficits but impairs learning/memory in C57BL/6 mice. Sci. Rep., 9(1), 2019, 6673.
Dutra, R.C., Moreira, E.L., Alberti, T.B., Marcon, R., Prediger, R.D., Calixto, J.B., Spatial reference memory deficits precede motor dysfunction in an experimental autoimmune encephalomyelitis model: the role of kallikrein-kinin system. Brain Behav. Immun. 33 (2013), 90–101.
Fox, D. 3rd, Burgin, A.B., Gurney, M.E., Structural basis for the design of selective phosphodiesterase 4B inhibitors. Cell. Signal. 26:3 (2014), 657–663.
Fox, R.J., Coffey, C.S., Cudkowicz, M.E., Gleason, T., Goodman, A., Klawiter, E.C., et al. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemp. Clin. Trials 50 (2016), 166–177.
Fox, R.J., Coffey, C.S., Conwit, R., Cudkowicz, M.E., Gleason, T., Goodman, A., et al. Phase 2 trial of ibudilast in progressive multiple sclerosis. N. Engl. J. Med. 379:9 (2018), 846–855.
Garcia-Leon, J.A., Garcia-Diaz, B., Eggermont, K., Caceres-Palomo, L., Neyrinck, K., Madeiro da Costa, R., et al. Generation of oligodendrocytes and establishment of an all-human myelinating platform from human pluripotent stem cells. Nat. Protoc. 15:11 (2020), 3716–3744.
Gonzalez-Garcia, C., Bravo, B., Ballester, A., Gomez-Perez, R., Eguiluz, C., Redondo, M., et al. Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis. Br. J. Pharmacol. 170:3 (2013), 602–613.
Hamano, S., Himeno, K., Miyazaki, Y., Ishii, K., Yamanaka, A., Takeda, A., et al. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 19:5 (2003), 657–667.
Hatzelmann, A., Morcillo, E.J., Lungarella, G., Adnot, S., Sanjar, S., Beume, R., et al. The preclinical pharmacology of roflumilast–a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 23:4 (2010), 235–256.
Hedde, J.R., Hanks, A.N., Schmidt, C.J., Hughes, Z.A., The isozyme selective phosphodiesterase-4 inhibitor, ABI-4, attenuates the effects of lipopolysaccharide in human cells and rodent models of peripheral and CNS inflammation. Brain Behav. Immun. 64 (2017), 285–295.
Henze, T., Rieckmann, P., Toyka, K.V., Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis S. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur. Neurol. 56:2 (2006), 78–105.
Hou, B., Zhang, Y., Liang, P., He, Y., Peng, B., Liu, W., et al. Inhibition of the NLRP3-inflammasome prevents cognitive deficits in experimental autoimmune encephalomyelitis mice via the alteration of astrocyte phenotype. Cell Death Dis., 11(5), 2020, 377.
Houslay, M.D., Schafer, P., Zhang, K.Y., Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov. Today 10:22 (2005), 1503–1519.
Jin, S.L., Lan, L., Zoudilova, M., Conti, M., Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J. Immunol. 175:3 (2005), 1523–1531.
Johnson, K.R., Nicodemus-Johnson, J., Danziger, R.S., An evolutionary analysis of cAMP-specific Phosphodiesterase 4 alternative splicing. BMC Evol. Biol., 10, 2010, 247.
Kappos, L., Bar-Or, A., Cree, B.A.C., Fox, R.J., Giovannoni, G., Gold, R., et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391:10127 (2018), 1263–1273.
Koga, K., Takaesu, G., Yoshida, R., Nakaya, M., Kobayashi, T., Kinjyo, I., et al. Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity 30:3 (2009), 372–383.
Kotter, M.R., Stadelmann, C., Hartung, H.P., Enhancing remyelination in disease–can we wrap it up?. Brain 134:Pt 7 (2011), 1882–1900.
Kuhlmann, T., Miron, V., Cui, Q., Wegner, C., Antel, J., Bruck, W., Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131:Pt 7 (2008), 1749–1758.
Locri, F., Cammalleri, M., Pini, A., Dal Monte, M., Rusciano, D., Bagnoli, P., Further Evidence on Efficacy of Diet Supplementation with Fatty Acids in Ocular Pathologies: Insights from the EAE Model of Optic Neuritis. Nutrients, 10(10), 2018.
Lucchinetti, C.F., Bruck, W., Rodriguez, M., Lassmann, H., Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6:3 (1996), 259–274.
Maheshwari, A., Janssens, K., Bogie, J., Van Den Haute, C., Struys, T., Lambrichts, I., et al. Local overexpression of interleukin-11 in the central nervous system limits demyelination and enhances remyelination. Mediators Inflamm., 2013, 2013, 685317.
Marenna, S., Huang, S.C., Dalla Costa, G., d'Isa, R., Castoldi, V., Rossi, E., et al. Visual evoked potentials to monitor myelin cuprizone-induced functional changes. Front. Neurosci., 16, 2022, 820155.
McDonough, W., Aragon, I.V., Rich, J., Murphy, J.M., Abou Saleh, L., Boyd, A., et al. PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice. FASEB J. 34:9 (2020), 12533–12548.
Mohammadnejad, A., Li, W., Lund, J.B., Li, S., Larsen, M.J., Mengel-From, J., et al. Global gene expression profiling and transcription factor network analysis of cognitive aging in monozygotic twins. Front. Genet., 12, 2021, 675587.
Mori, F., Perez-Torres, S., De Caro, R., Porzionato, A., Macchi, V., Beleta, J., et al. The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. J. Chem. Neuroanat. 40:1 (2010), 36–42.
Mosenden, R., Tasken, K., Cyclic AMP-mediated immune regulation–overview of mechanisms of action in T cells. Cell. Signal. 23:6 (2011), 1009–1016.
Myers, S.A., Gobejishvili, L., Saraswat Ohri, S., Garrett Wilson, C., Andres, K.R., Riegler, A.S., et al. Following spinal cord injury, PDE4B drives an acute, local inflammatory response and a chronic, systemic response exacerbated by gut dysbiosis and endotoxemia. Neurobiol. Dis. 124 (2019), 353–363.
Nelissen, E., van Goethem, N.P., Bonassoli, V.T., Heckman, P.R.A., van Hagen, B.T.J., Suay, D., et al. Validation of the xylazine/ketamine anesthesia test as a predictor of the emetic potential of pharmacological compounds in rats. Neurosci. Lett. 699 (2019), 41–46.
Neyrinck, K., Garcia-Leon, J.A., Single Transcription Factor-Based Differentiation Allowing Fast and Efficient Oligodendrocyte Generation via SOX10 Overexpression. Methods Mol. Biol. 2352 (2021), 149–170.
Ontaneda, D., Thompson, A.J., Fox, R.J., Cohen, J.A., Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet 389:10076 (2017), 1357–1366.
Paes, D., Schepers, M., Rombaut, B., van den Hove, D., Vanmierlo, T., Prickaerts, J., The molecular biology of phosphodiesterase 4 enzymes as pharmacological targets: an interplay of isoforms, conformational states, and inhibitors. Pharmacol. Rev. 73:3 (2021), 1016–1049.
Peng, H., Bria, A., Zhou, Z., Iannello, G., Long, F., Extensible visualization and analysis for multidimensional images using Vaa3D. Nat. Protoc. 9:1 (2014), 193–208.
Peng, T., Qi, B., He, J., Ke, H., Shi, J., Advances in the development of phosphodiesterase-4 inhibitors. J. Med. Chem. 63:19 (2020), 10594–10617.
Peter, D., Jin, S.L., Conti, M., Hatzelmann, A., Zitt, C., Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J. Immunol. 178:8 (2007), 4820–4831.
Prineas, J.W., Wright, R.G., Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab. Invest. 38:4 (1978), 409–421.
Qin, J., Sikkema, A.H., van der Bij, K., de Jonge, J.C., Klappe, K., Nies, V., et al. GD1a overcomes inhibition of myelination by fibronectin via activation of protein kinase a: implications for multiple sclerosis. J. Neurosci. 37:41 (2017), 9925–9938.
Raible, D.W., McMorris, F.A., Cyclic AMP regulates the rate of differentiation of oligodendrocytes without changing the lineage commitment of their progenitors. Dev. Biol. 133:2 (1989), 437–446.
Raible, D.W., McMorris, F.A., Oligodendrocyte differentiation and progenitor cell proliferation are independently regulated by cyclic AMP. J. Neurosci. Res. 34:3 (1993), 287–294.
Reyes-Irisarri, E., Sanchez, A.J., Garcia-Merino, J.A., Mengod, G., Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis. J. Neuropathol. Exp. Neurol. 66:10 (2007), 923–931.
Ricciarelli, R., Brullo, C., Prickaerts, J., Arancio, O., Villa, C., Rebosio, C., et al. Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease. Sci. Rep., 7, 2017, 46320.
Richter, W., Menniti, F.S., Zhang, H.T., Conti, M., PDE4 as a target for cognition enhancement. Expert Opin. Ther. Targets 17:9 (2013), 1011–1027.
Ridder, W.H. 3rd, Nusinowitz, S., The visual evoked potential in the mouse–origins and response characteristics. Vision Res. 46:6–7 (2006), 902–913.
Robichaud, A., Stamatiou, P.B., Jin, S.L., Lachance, N., MacDonald, D., Laliberte, F., et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 110:7 (2002), 1045–1052.
Sanabra, C., Johansson, E.M., Mengod, G., Critical role for PDE4 subfamilies in the development of experimental autoimmune encephalomyelitis. J. Chem. Neuroanat. 47 (2013), 96–105.
Santiago, A., Soares, L.M., Schepers, M., Milani, H., Vanmierlo, T., Prickaerts, J., et al. Roflumilast promotes memory recovery and attenuates white matter injury in aged rats subjected to chronic cerebral hypoperfusion. Neuropharmacology 138 (2018), 360–370.
Schepers, M., Tiane, A., Paes, D., Sanchez, S., Rombaut, B., Piccart, E., et al. Targeting phosphodiesterases-towards a tailor-made approach in multiple sclerosis treatment. Front. Immunol., 10, 2019, 1727.
Sekyi, M.T., Lauderdale, K., Atkinson, K.C., Golestany, B., Karim, H., Feri, M., et al. Alleviation of extensive visual pathway dysfunction by a remyelinating drug in a chronic mouse model of multiple sclerosis. Brain Pathol. 31:2 (2021), 312–332.
Shen, M.W., Arbab, M., Hsu, J.Y., Worstell, D., Culbertson, S.J., Krabbe, O., et al. Predictable and precise template-free CRISPR editing of pathogenic variants. Nature 563:7733 (2018), 646–651.
Shi, Y., Lv, J., Chen, L., Luo, G., Tao, M., Pan, J., et al. Phosphodiesterase-4D knockdown in the prefrontal cortex alleviates memory deficits and synaptic failure in mouse model of alzheimer's disease. Front. Aging Neurosci., 13, 2021, 722580.
Sierksma, A.S., van den Hove, D.L., Pfau, F., Philippens, M., Bruno, O., Fedele, E., et al. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D. Neuropharmacology 77 (2014), 120–130.
Smith, S.J., Brookes-Fazakerley, S., Donnelly, L.E., Barnes, P.J., Barnette, M.S., Giembycz, M.A., Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 284:2 (2003), L279–L289.
Sommer, N., Martin, R., McFarland, H.F., Quigley, L., Cannella, B., Raine, C.S., et al. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J. Neuroimmunol. 79:1 (1997), 54–61.
Sonar, S.A., Lal, G., Differentiation and transmigration of CD4 T cells in neuroinflammation and autoimmunity. Front. Immunol., 8, 2017, 1695.
Stumhofer, J.S., Laurence, A., Wilson, E.H., Huang, E., Tato, C.M., Johnson, L.M., et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7:9 (2006), 937–945.
Sunke, R., Bankala, R., Thirupataiah, B., Ramarao, E., Kumar, J.S., Doss, H.M., et al. InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis. Eur. J. Med. Chem. 174 (2019), 198–215.
Syed, Y.A., Baer, A., Hofer, M.P., Gonzalez, G.A., Rundle, J., Myrta, S., et al. Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination. EMBO Mol. Med. 5:12 (2013), 1918–1934.
Talla, V., Yu, H., Chou, T.H., Porciatti, V., Chiodo, V., Boye, S.L., et al. NADH-dehydrogenase type-2 suppresses irreversible visual loss and neurodegeneration in the EAE animal model of MS. Mol. Ther. 21:10 (2013), 1876–1888.
Thompson, K.K., Tsirka, S.E., Guanabenz modulates microglia and macrophages during demyelination. Sci. Rep., 10(1), 2020, 19333.
Tiane, A., Schepers, M., Riemens, R., Rombaut, B., Vandormael, P., Somers, V., et al. DNA methylation regulates the expression of the negative transcriptional regulators ID2 and ID4 during OPC differentiation. Cell. Mol. Life Sci. 78:19–20 (2021), 6631–6644.
Trojano, M., Paolicelli, D., Bellacosa, A., Cataldo, S., The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. Neurol. Sci. 24:Suppl 5 (2003), S268–S270.
Ugarte, A., Gil-Bea, F., Garcia-Barroso, C., Cedazo-Minguez, A., Ramirez, M.J., Franco, R., et al. Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease. Neuropathol. Appl. Neurobiol. 41:4 (2015), 471–482.
Vanmierlo, T., Rutten, K., Dederen, J., Bloks, V.W., van Vark-van der Zee, L.C., Kuipers, F., et al. Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol. Aging 32:7 (2011), 1262–1272.
Vanmierlo, T., Creemers, P., Akkerman, S., van Duinen, M., Sambeth, A., De Vry, J., et al. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses. Behav. Brain Res. 303 (2016), 26–33.
Vilhena, E.R., Bonato, J.M., Schepers, M., Kunieda, J.K.C., Milani, H., Vanmierlo, T., et al. Positive effects of roflumilast on behavior, neuroinflammation, and white matter injury in mice with global cerebral ischemia. Behav. Pharmacol. 32:6 (2021), 459–471.
Villarino, A., Hibbert, L., Lieberman, L., Wilson, E., Mak, T., Yoshida, H., et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19:5 (2003), 645–655.
Wang, S.S., Bi, H.Z., Chu, S.F., Dong, Y.X., He, W.B., Tian, Y.J., et al. CZ-7, a new derivative of Claulansine F, promotes remyelination induced by cuprizone by enhancing myelin debris clearance. Brain Res. Bull. 159 (2020), 67–78.
Weiner, H.L., The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 65:3 (2009), 239–248.
Whitaker, C.M., Beaumont, E., Wells, M.J., Magnuson, D.S., Hetman, M., Onifer, S.M., Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury. Neurosci. Lett. 438:2 (2008), 200–204.
Wingerchuk, D.M., Carter, J.L., Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin. Proc. 89:2 (2014), 225–240.
Wolinsky, J.S., Arnold, D.L., Brochet, B., Hartung, H.P., Montalban, X., Naismith, R.T., et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 19:12 (2020), 998–1009.
Wolswijk, G., Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J. Neurosci. 18:2 (1998), 601–609.
Wouters, K., Cudejko, C., Gijbels, M.J., Fuentes, L., Bantubungi, K., Vanhoutte, J., et al. Bone marrow p16INK4a-deficiency does not modulate obesity, glucose homeostasis or atherosclerosis development. PLoS One, 7(3), 2012, e32440.
Wucherpfennig, K.W., Newcombe, J., Li, H., Keddy, C., Cuzner, M.L., Hafler, D.A., T cell receptor V alpha-V beta repertoire and cytokine gene expression in active multiple sclerosis lesions. J. Exp. Med. 175:4 (1992), 993–1002.
Xiang, J., Wang, X., Gao, Y., Li, T., Cao, R., Yan, T., et al. Phosphodiesterase 4D gene modifies the functional network of patients with mild cognitive impairment and Alzheimer's disease. Front. Genet., 11, 2020, 890.
Yang, J.X., Hsieh, K.C., Chen, Y.L., Lee, C.K., Conti, M., Chuang, T.H., et al. Phosphodiesterase 4B negatively regulates endotoxin-activated interleukin-1 receptor antagonist responses in macrophages. Sci. Rep., 7, 2017, 46165.
Yang, G., McIntyre, K.W., Townsend, R.M., Shen, H.H., Pitts, W.J., Dodd, J.H., et al. Phosphodiesterase 7A-deficient mice have functional T cells. J. Immunol. 171:12 (2003), 6414–6420.
Yoshimura, T., Takeda, A., Hamano, S., Miyazaki, Y., Kinjyo, I., Ishibashi, T., et al. Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. J. Immunol. 177:8 (2006), 5377–5385.
Zawadzka, M., Rivers, L.E., Fancy, S.P., Zhao, C., Tripathi, R., Jamen, F., et al. CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell 6:6 (2010), 578–590.
Zhang, C., Cheng, Y., Wang, H., Wang, C., Wilson, S.P., Xu, J., et al. RNA interference-mediated knockdown of long-form phosphodiesterase-4D (PDE4D) enzyme reverses amyloid-beta42-induced memory deficits in mice. J. Alzheimers Dis. 38:2 (2014), 269–280.
Zhang, C., Xu, Y., Zhang, H.T., Gurney, M.E., O'Donnell, J.M., Comparison of the pharmacological profiles of selective PDE4B and PDE4D inhibitors in the central nervous system. Sci. Rep., 7, 2017, 40115.
Zhang, C., Xu, Y., Chowdhary, A., Fox, D. 3rd, Gurney, M.E., Zhang, H.T., et al. Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice. Neuropsychopharmacology 43:11 (2018), 2299–2309.
